Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program

Journal of the American College of Cardiology

Volumn 47, Issue 10, 2006, Pages 1997-2004

  Olsson, Lars G ^a   Swedberg, Karl ^a   Ducharme, Anique ^b   Granger, Christopher B ^c   Michelson, Eric L ^d   McMurray, John J V ^e   Puu, Margareta ^f   Yusuf, Salim ^g   Pfeffer, Marc A ^h  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b MONTREAL HEART INSTITUTE   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

^e WESTERN INFIRMARY   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g McMaster Clinic   (Canada)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SPIRONOLACTONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK; STROKE VOLUME; TETRAZOLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33646254610     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.01.060     Document Type: Article

References (31)

1. Maisel W.H., and Stevenson L.W. Atrial fibrillation in heart failure. epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91 (2003) 2D-8D
2. Kannel W.B., and Belanger A.J. Epidemiology of heart failure. Am Heart J 121 (1991) 951-957
3. Daoud E.G., Weiss R., Bahu M., et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 78 (1996) 1433-1436
4. Clark D.M., Plumb V.J., Epstein A.E., and Kay G.N. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 30 (1997) 1039-1045
5. Carson P.E., Johnson G.R., Dunkman W.B., Fletcher R.D., Farrell L., Cohn J.N., and The V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. Circulation 87 Suppl (1993) VI102-VI110
6. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., and Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies Of Left Ventricular Dysfunction. J Am Coll Cardiol 32 (1998) 695-703
7. Crijns H.J., Tjeerdsma G., deKam P.J., et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 21 (2000) 1238-1245
8. Swedberg K., Olsson L.G., Charlesworth A., et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers. results from COMET. Eur Heart J 26 (2005) 1303-1308
9. Middlekauff H.R., Stevenson W.G., and Stevenson L.W. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 84 (1991) 40-48
10. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Improving survival for patients with advanced heart failure. a study of 737 consecutive patients. J Am Coll Cardiol 26 (1995) 1417-1423
11. Mahoney P., Kimmel S., DeNofrio D., Wahl P., and Loh E. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 83 (1999) 1544-1547
12. Ahmed A., Thornton P., Perry G.J., Allman R.M., and DeLong J.F. Impact of atrial fibrillation on mortality and readmission in older adults hospitalized with heart failure. Eur J Heart Fail 6 (2004) 421-426
13. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. the Framingham Heart Study. Circulation 107 (2003) 2920-2925
14. Hogg K., Swedberg K., and McMurray J. Heart failure with preserved left ventricular systolic function. epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43 (2004) 317-327
15. Philbin E.F., Rocco T.A., Lindenmuth N.W., Ulrich K., and Jenkins P.L. Systolic versus diastolic heart failure in community practice. clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 109 (2000) 605-613
16. Gustafsson F., Torp-Pedersen C., Brendorp B., Seibaek M., Burchardt H., and Kober L. Long-term survival in patients hospitalized with congestive heart failure. relation to preserved and reduced left ventricular systolic function. Eur Heart J 24 (2003) 863-870
17. Smith G.L., Masoudi F.A., Vaccarino V., Radford M.J., and Krumholz H.M. Outcomes in heart failure patients with preserved ejection fraction. mortality, readmission, and functional decline. J Am Coll Cardiol 41 (2003) 1510-1518
18. Tarantini L., Faggiano P., Senni M., et al. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure. Ital Heart J 3 (2002) 656-664
19. Lenzen M.J., Scholte O.P., Reimer W.J., Boersma E., et al. Differences between patients with a preserved and a depressed left ventricular function. a report from the EuroHeart Failure Survey. Eur Heart J 25 (2004) 1214-1220
20. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure. the CHARM-Overall programme. Lancet 362 (2003) 759-766
21. Swedberg K., Pfeffer M., Granger C., et al., CHARM-Programme Investigators. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM). rationale and design. J Card Fail 5 (1999) 276-282
22. Tsang T.S., Gersh B.J., Appleton C.P., et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40 (2002) 1636-1644
23. Masoudi F.A., Havranek E.P., Smith G., et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 41 (2003) 217-223
24. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 712-719
25. Khand A.U., Rankin A.C., Martin W., Taylor J., Gemmell I., and Cleland J.G. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol 42 (2003) 1944-1951
26. Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 (2003) 464-474
27. Solomon S.D., Wang D., Finn P., et al. Effect of candesartan on cause-specific mortality in heart failure patients. the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 110 (2004) 2180-2183
28. Mathew J., Hunsberger S., Fleg J., McSherry F., Williford W., and Yusuf S. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 118 (2000) 914-922
29. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure. results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149 (2005) 548-557
30. Ducharme A., Swedberg K., Pfeffer M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan. Am Heart J (2006) In press
31. Wachtell K., Hornestam B., Lehto M., et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation. the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005) 705-711